Author Archives: admin


Shared protein fingerprint could simplify treatment of common inherited heart disease – University of Wisconsin-Madison

Hypertrophic cardiomyopathy is the most common inherited heart disease, marked by an abnormally thickened heart muscle that can obstruct blood flow and lead to sudden death in young adults.

A dizzying array of over 1,400 genetic mutations can lead to the disease, puzzling doctors on how to treat so many unique varieties. But in new research, University of WisconsinMadison scientists discovered that many different genetic mutations result in surprisingly similar changes to heart muscle proteins in patients with the most severe manifestations of hypertrophic cardiomyopathy. This shared protein fingerprint suggests that shared treatments could treat the disease.

This could be good news for doctors treating obstructive hypertrophic cardiomyopathy patients, because our data suggest theres a convergent pathway in these patients, allowing development of treatments that generally target patients with severe obstruction from their cardiomyopathy instead of targeting a patients individual genetic mutations, says Ying Ge, a professor of cell and regenerative biology and chemistry at UWMadison who headed the new study.

Ying Ge

Ge and an international collaboration of researchers published their findings the week of Sept. 21 in the Proceedings of the National Academy of Sciences. UWMadison graduate students Trisha Tucholski and Wenxuan Cai led the work, which analyzed in detail the protein signatures of diseased and normal hearts using advanced protein-measurement technology.

The team collected samples of diseased heart tissue from 16 patients who underwent corrective surgery to fix impaired blood flow in their hearts. Hypertrophic cardiomyopathy in eight of these patients was due to eight distinct mutations across two genes; for the other eight patients, the disease-causing mutations were unknown. Proteins from the diseased heart samples were compared to those from healthy donor hearts.

Despite the variation in underlying genetic mutations, Ges team discovered a general pattern in hearts from patients with the disease. For example, many key muscle proteins from diseased hearts had fewer molecular tags known as phosphates. While the exact consequence of having fewer phosphates is unknown, its likely that these altered proteins contribute to a general state of dysregulation in the heart, leading to the thickened muscle characteristic of the disease.

The findings reinforce that genetic mutations arent always enough to explain diseases, says Ge. The proteins those genes encode have the ultimate impact on health, and the bodys proteins can be altered in subtle but consequential ways during disease.

When we first performed these experiments, this similarity at the protein level was quite surprising to us because it is generally expected that different mutations could lead to different changes in the proteins, says Ge. But in reality, these results make sense, because when the patients with this disease present to the hospital for surgery, their hearts exhibit similar dysfunction.

The results are still preliminary. Ges group wants to expand to study hundreds of additional patients with a wide array of underlying hypertrophic cardiomyopathy mutations to see if the similar protein fingerprint trend holds. They also plan to study heart stem cells with disease-causing mutations in an effort to study early stages of the disease, which isnt possible with human patients.

But with additional research, this kind of in-depth analysis of protein fingerprints could guide future treatments.

This data opens the door with evidence showing that protein-level changes might be a better reflection of the patients disease than their genes, and if we can examine patients samples at the protein level, that could help us provide precision-medicine treatments, says Ge.

This work was supported in part by the National Institutes of Health (grants R01 HL096971, R01 GM117058, GM125085, HL109810, S10 OD018475, T32 GM008505, T32 GM008688, R01 HL129798, U01 HL134764, and R01 HL139883) and the National Science Foundation (grant EEC-1648035).

Share via Facebook

Share via Twitter

Share via Linked In

Share via Email

Follow this link:
Shared protein fingerprint could simplify treatment of common inherited heart disease - University of Wisconsin-Madison

COVID is shifting the conversation about the medical application of CBD – Open Access Government

COVID-19 has spread around the planet, sending billions of people into lockdown as health services struggle to cope. The statistics are startling global cases stand at 23,139,628 and with a total death toll of 801,795 and new daily cases rising (John Hopkins University data 23 Aug 2020), the outbreak has thrown an unprecedented challenge to the world and its citizens. So far, there is no approved treatment or vaccine.

While researchers around the world continue to explore different ways in combating COVID-19, some are looking into how cannabis derived CBD can offer benefits for those suffering from severe forms of this infection.

One recent study from the Dental College of Georgia and Medical College of Georgiashowed high CBD formulations could be effective in the treatment of acute respiratory distress syndrome, or ARDS. The condition, also known as a cytokine storm, has been seen in serious cases of coronavirus, and even affects patients with other viruses or autoimmune diseases. With ARDS, the patients own hyperactive autoimmune system inundates organs with cytokines, resulting in dangerous inflammation. This reaction can cause lung damage and eventual death in COVID-19 victims.

The study model showed CBD down-regulated the cytokines, which helped improve oxygen levels and supported recovery of damaged lung tissues. The researchers also intend to perform similar studies to understand how CBD might help other organs recover from the effects of the virus. Researchers from University of Nebraska and the Texas Biomedical Research Institute also took part. In apeer-reviewed article in Brain, Behaviour, and Immunity, the authors said further research is needed to understand if CBD can help patients infected by the virus.

Now early results from an ongoing Israeli study is adding to the growing evidence that cannabis ingredients could be a game changing treatment in the fight against COVID-19. The new terpene study is being performed by two Israeli research and development companies,Eybnawhich specializes in terpene based medicines, and CannaSoul Analytics. The study looks at a proprietary terpene formulation called NT-VRL, which was created by Eybna to treat inflammatory conditions such as the cytokine storm syndrome found in COVID-19 patients. The formulation contains 30 individual terpenes that are potential anti-inammatory agents all working together to create a positive impact.

While results are ongoing and are yet to be completed, peer reviewed or published, these are positive steps that warrants further investigation into the application of CBD.

This is far from the only investigation into CBD medical benefits.

Researchers at the University of Lethbridge in Alberta,Canada, revealed at the beginning of July that certain kinds of high CBD strains could help treat people infected with the virus or even prevent it from developing in the first place by managing to reduce virus receptors.

Study authors found extract from high CBD strains could help to regulate an enzyme that coronavirus attaches to thereby blocking the viruss ability to infect cells. Results were published on peer review website Preprints.

In Israel, there are several companies and trials underway on how CBD can be used to battle COVID-19. One such example is the partnership of InnoCan Pharma and Tel Aviv University who are working on a new treatment for COVID-19 using exosomes loaded with CBD. Exosomes are small particles created when stem cells multiply. The method will utilise the exosomes as homing missiles, as they can uniquely target cell organs that have been damaged.

As it stands, CBD is still an area under development for the treatment of COVID-19. While there have been some promising results on CBDs anti-inflammatory properties, more studies are needed before leading into clinical trials to test effectiveness. This can take anywhere from months to years.

Speed, agility, and innovation are required from governments, businesses, and society in crafting responses to cope with this evolving new normal. In this period of uncertainty, every therapeutic opportunity and avenue must be considered. CBD opens the door to various exciting possibilities.

Read the rest here:
COVID is shifting the conversation about the medical application of CBD - Open Access Government

Remarkable Growth in the Artificial Embryo Market by top key players like MERLN Institute of Maastricht University, University of Cambridge,…

A2Z Market Research announces the release of the Artificial Embryo Market research report. The market is predicted to grow at a healthy pace in the coming years. Artificial Embryo Market 2020 research report presents an analysis of market size, share, and growth, trends, cost structure, statistical and comprehensive data of the global market. The Market report offers remarkable data regarding the industrys growth parameters, the current state of the market in terms of analysis of possible economic situations, and macroeconomic analysis.

An artificial embryo is an embryo prepared by the use of various technologies in artificial conditions with the help of stem cells. These cells are grown in culture media which provides the required nutrition for the growth. increase in stem cell banking and various other advanced technologies are expected to promote the growth of the Artificial Embryo Market.

The artificial Embryo Market is growing at a CAGR of +10% during the forecast period 2020-2026.

Sample Report with Latest Industry Trends @:

https://www.a2zmarketresearch.com/sample?reportId=313209

The top companies in this report include:

MERLN Institute of Maastricht University, University of Cambridge, University of Michigan, Rockefeller University, MRC London Institute of Medical Sciences

This report provides an in-depth review of the current state of the Artificial Embryo market, daring its growth and all other essential elements in all of the major markets of the county.It presents a gigantic amount of market data, compiled using myriad primary and secondary research practices.The data in this report has been reduced on a business basis using various systematic methods.

For a comprehensive analysis, the Artificial Embryo market is segmented by product type, region, and application.Due to its regional focus, the market is alien to North America, Europe, Asia-Pacific, the Middle East and Africa as well as Latin America.Major companies are working on distributing their products and services across different regions.In addition, procurements and associations from some of the leading organizations.All of the factors intended to drive the global marketplace are examined in depth.

Get Impressive [emailprotected]:

https://www.a2zmarketresearch.com/discount?reportId=313209

This report gives an in-depth and broad understanding of the Artificial Embryo Market. With exact data cover all key features of the current market, this report offers widespread data on leading companies. Appreciative of the market state by amenability of correct historical data regarding each and every sector for the forecast period is mentioned. Driving forces, restraints, and opportunities are given to help give an improved picture of this market investment for the forecast period of 2020 to 2026.

Key Factors Impacting Market Growth:

o Convergence of data with accuracy and high speed o Rising demand for efficient computing o Increasing opportunities through improved research, computation, and data analysis performances o High price and data security issues

The main questions answered in the report are:

Reasons to Purchase this Report:

* Estimates 2020-2026 Artificial Embryo Market development trends with the recent trends and SWOT analysis

* Market dynamics scenario, along with growth opportunities of the market in the years to come

* Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects

* Regional and country-level analysis integrating the demand and supply forces that are influencing the growth of the market.

* Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years

* Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players

Buy Exclusive Report @:

https://www.a2zmarketresearch.com/buy?reportId=313209

About A2Z Market Research:

The A2Z Market Research library provides syndication reports from market researchers around the world. Ready-to-buy syndication Market research studies will help you find the most relevant business intelligence.

Our Research Analyst Provides business insights and market research reports for large and small businesses.

The company helps clients build business policies and grow in that market area. A2Z Market Research is not only interested in industry reports dealing with telecommunications, healthcare, pharmaceuticals, financial services, energy, technology, real estate, logistics, F & B, media, etc. but also your company data, country profiles, trends, information and analysis on the sector of your interest.

Contact Us:

Roger Smith

1887 WHITNEY MESA DR HENDERSON, NV 89014

[emailprotected]

+1 775 237 4147

Excerpt from:
Remarkable Growth in the Artificial Embryo Market by top key players like MERLN Institute of Maastricht University, University of Cambridge,...

Global Induced Pluripotent Stem Cells (iPSCs) Market 2020 Manufacturer Analysis, Technology Advancements, Industry Scope and Forecast to 2027||Fate…

Key Developments in the Market:

In March 2018, Kaneka Corporation announced that they have acquired a patent in the Japan for the creation of the method to mass-culture pluripotent stem cells including iPS cells and ES cells. This will help the company to use the technology to produce high quality pluripotent stem cells which can be used in the drug and cell therapy.

In March 2015, Fujifilm announced that they have acquired Cellular Dynamics International. The main aim of the acquisition is to expand their business in the iPS cell-based drug discovery support service with the use of CDS technology. It will help them to product high- quality automatic human cells with the help of the induced pluripotent stem cells. This will help the company to be more competitive in the drug discovery and regenerative medicine.

Now Get 20% Discount on This Report @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-induced-pluripotent-stem-cells-market

Global Induced Pluripotent Stem Cells (iPSCs) Market Scope and Market Size

Induced pluripotent stem cells (iPSCs) market is segmented of the basis of derived cell type, application and end- user. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

Global Induced Pluripotent Stem Cells (iPSCs) Market Drivers:

Increasing R&D investment activities is expected to create new opportunity for the market.

Increasing demand for personalized regenerative cell therapies among medical researchers & healthcare is expected to enhance the market growth. Some of the other factors such as increasing cases of chronic diseases, growing awareness among patient, rising funding by government & private sectors and rising number ofclinical trialsis expected to drive the induced pluripotent stem cells (iPSCs) market in the forecast period of 2020 to 2027.

High cost of the induced pluripotent stem cells (iPSCs) and increasing ethical issues & lengthy processes is expected to hamper the market growth in the mentioned forecast period.

Access Full report @https://www.databridgemarketresearch.com/reports/global-induced-pluripotent-stem-cells-market

About Data Bridge Market Research

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune. We ponder into the heterogeneous markets in accord with our clients needs and scoop out the best possible solutions and detailed information about the market trends. Data Bridge delve into the markets across Asia, North America, South America, Africa to name few.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact: Data Bridge Market Research Tel: +1-888-387-2818 Email:Corporatesales@databridgemarketresearch.com

Read the original post:
Global Induced Pluripotent Stem Cells (iPSCs) Market 2020 Manufacturer Analysis, Technology Advancements, Industry Scope and Forecast to 2027||Fate...

Election 2020: Prop. 14 and stem cell research funding – KCBX

In November, California voters will be deciding on a dozen statewide ballot measures. One is about funding stem cell research through bonds, Proposition 14.

Just one day before his high school graduation, Cal Poly football recruit Jake Javier dove into a friends swimming pool and hit his head on the bottom, leaving him paralyzed from the chest down.

The next thing I knew I was being told Im a quadriplegic," Javier said. "I broke my neck at the C6 level.

Javiers plans to play football in collegenow gone. He was told he was never going to walk again.

I really didnt have time to panic, or feel sorry for myself," Javier said. "Immediately it was survival mode for the next couple weeks, I was on a ventilator [and] couldnt breathe, and then from there it was starting my rehab.

Less than a week post-injury, he got a call from a Stanford doctor who said the teen would make a great candidate for a stem cell trial they were conducting.

They were very clear about the possible outcomes of it," Javier said. "They were like yeah it could potentially help you we dont know how much, it could potentially negatively affect you and hurt your function.'"

Javier decided even if it wouldnt help him, the research could help others, so he became a part of the trial. Doctors injected stem cells in him in a one-time surgery, then monitored and tested Javier's progress for months. He says he had a positive outcome.

I regained more strength in my arms than what was expected, I have a little bit of finger movement that isnt a whole lot, but it's functional," Javier said. "Honestly Im really glad I went through with it because I have no idea where Id be without it.

This election, California voters will decide whether to pay for more stem cell research like this via Proposition 14. It continues programs approved by voters in 2004.

A UC San Diego professor of cellular and molecular medicine, Lawrence Goldstein, says it will fund research and therapy for Alzheimers, Parkinsons, cancer, and other brain and central nervous system diseases and conditions.

It would authorize five and a half billion dollars," Goldstein said. "In what are called general obligation funds that would then be used to fund stem cell research in medicine.

Opponents argue with California facing a huge budget deficit due to the pandemic, Prop. 14 would take billions away from more pressing needs like housing and education. And that back in 2004, state voters approved funding because the federal government wasnt supporting stem cell research, but thats no longer the case.

See the original post:
Election 2020: Prop. 14 and stem cell research funding - KCBX

Hair Regeneration Therapy Company Stemson Therapeutics Raises $7.5 Million – Pulse 2.0

Stemson Therapeutics announced that it has raised a $7.5 million seed round of funding led by Allergan Aesthetics (an AbbVie Company) and impact investor Fortunis Capital to advance the development of Stemsons therapeutic solution to cure hair loss. This funding round enables Stemson to advance its goal of restoring human hair growth with a novel approach using the patients own cells to generate new hair follicles.

Allergan Aesthetics is known as a world-leading medical aesthetics company. And Fortunis Capital is committed to continuing support of Stemsons regenerative cell therapy to treat hair loss through its new Impact Fund which intends to invest in companies that offer significant social or environmental benefit.

The seed funding round supports the preclinical development of Stemsons Induced Pluripotent Stem Cell (iPSC) based technology which is capable of producing the cell types required to initiate hair follicle growth. And globally, hundreds of millions of men and women suffer from various forms of hair loss and no solution today is capable of generating a new supply of follicles for patients in need.

The initial seed financing round enables Stemson to expand its management team and R&D resources while recent approval of a foundational patent provides stability surrounding the companys efforts to develop its radical solution for hair growth. The additions of Meghan Samberg, Ph.D. as Vice President of R&D and Preclinical Development and Cenk Sumen, Ph.D. as Chief Technology Officer complement the work of Stemsons cofounder and Chief Scientific Officer Dr. Alexey Terskikh and the R&D team.

Stemson received approval in the United States of its cornerstone Human Induced Pluripotent Stem Cell (iPSC) method patent licensed exclusively from the Sanford Burnham Prebys Medical Discovery Institute. And the patent covers a novel process developed by Dr. Terskikh to differentiate iPSC into dermal papilla cells, the cell type primarily responsible for controlling hair follicle generation and hair cycling. The patent secures foundational methods using iPSC cell therapy to grow hair.

KEY QUOTES:

Stemsons novel cell therapy approach to treat hair loss has game-changing potential. Their experienced management team is poised to elevate its proprietary regenerative cell therapy method as it begins the next phase of its preclinical program. Fortunis Capital is committed to supporting companies that are creating innovative solutions with worldwide social or environmental benefit, and we believe that Stemson has the team, technology and the tools in place to develop a therapy capable of solving the hair loss problem for millions of people in need.

Sir Andrew Ross, Director of Investments at Fortunis Capital

Allergan Aesthetics research and development efforts are focused on products and technologies that drive the advancement of aesthetics medicine. Hair loss is a significant unmet medical need for millions of men and women, and Stemson Therapeutics efforts to develop novel methods to regrow hair is an opportunity to make a difference in this area.

Yehia Hashad, M.D. Senior Vice President, Research and Development, Allergan Aesthetics.

Stemson has established the biological and technical building blocks which are needed to solve the problem of hair loss. A truly curative solution is now feasible, and we have built a world-class team to deliver a therapy for the millions of hair loss sufferers across the world. We are grateful for support from Allergan Aesthetics and Fortunis Capital, and we look forward to expanding our base of investors as we move toward our first human clinical trial.

Geoff Hamilton, cofounder and chief executive officer of Stemson Therapeutics

Excerpt from:
Hair Regeneration Therapy Company Stemson Therapeutics Raises $7.5 Million - Pulse 2.0

Could platelet-rich plasma therapy be the answer to your hair loss? – VOGUE India

Platelet-rich plasma, or PRP has been used for years to promise glowing, supple skin by way of the popular vampire facial. The same technology is now being co-opted to improve one of the most challenging aspects in dermatology: boosting hair growth and improving scalp health. We spoke to a dermatologist about the therapy to give you a low-down before you bring it up to your doctor.

Platelet rich plasma (PRP) is an extract of concentrated platelets from your own blood, says cosmetic physician and skincare expert Dr Jamuna Pai. Platelets contain packets of growth hormones and cytokines that increase the rebuilding of tissues to enhance healing. When PRP is injected into the area to be treated it restores blood flow, new cell growth, and tissue regeneration, says Dr Pai. Platelets, when injected deep into the scalp, may stimulate a specialised population of cells named dermal papilla cells, which play an important role in hair growth. The plasma promotes growth as it contains white blood cells and platelets, which can kickstart follicular activity and result in new hair growth. Not only has it been proven to improve the quantity, but it also affects the quality of hair increasing the thickness of the hair fibre.

This process involves drawing of blood from the patient, which is then put into a centrifuge to separate the protein-rich plasma. This platelet-rich plasma is then re-injected in the areas required, which in the case of hair loss is the scalp. A minimum of three sessions in an interval of four weeks is required to see appreciable results. One can continue the treatment up to six to nine sessions.You have to wait for eight to 12 weeks to see results. One can continue with sessions for maintenance even after the initial required number of sessions are over, and these sessions can be repeated once every two months for six to ninesessions, says Dr Pai. If the thought of multiple injections into the scalp sounds excruciating, Dr Pai says that pain management with PRP includes topical anaesthesia and icing. Since the injections are on the scalp and scalp is a dense tissue, there is a minimal amount of pain, although its quite bearable, she assures.

In cases of extreme hair loss, the underlying cause has to be detected and treated, which can range from hormonal disorders, stress, or vitamin and mineral deficiencies.Simultaneous PRP injections would help to restore the existing hair and also help the other hair roots to grow. It is always better to start early than late in cases of extreme hair fall because only a limited amount of hair can be restored. Therefore, time is of prime importance here, reminds Dr Pai. Once you begin the treatment, initial signs that tell you if it's working include reduction in hair fall and improvement in the health of the scalp skin.

While it may sound scary, there are no major side-effects to this therapy. Mild discomfort during the therapy and slight pain during the injection can be present. Side effects on the skin with PRP injections apart from the above mentioned can include mild bruising and swelling, Dr Pai says. The average width of the hair improves with PRP, which improves overall hair thickness. For the client to really see results, it takes three to four sessions but small hair starts growing as early as after the second session. The efficacy is 60 to 70 per cent improvement on an average, says Dr Pai.

Could your hormones be the reason behind your premature hair loss?

Would you roll tiny needles on your face if it gave you perfect skin?

7 ways you can increase skin collagen production

Read the original post:
Could platelet-rich plasma therapy be the answer to your hair loss? - VOGUE India

A passion for taking care of Steamboat’s active patients – Steamboat Pilot and Today

Dr. Alex Meininger didnt just know he wanted to be an orthopaedic surgeon someday. He specifically knew he wanted to practice in a ski resort town.

As a skier, competitive cyclist and outdoorsman, he understands the opportunity for work-life balance that living in a community such as Steamboat provides. It also offers him the chance to relate and socially interact with his patients, almost all of whom are fellow athletes and outdoor enthusiasts.

Maintaining an active lifestyle can also be an outlet and decompression for a stressful occupation, Dr. Meininger said.

Dr. Meininger specializes in sports medicine and minimally invasive arthroscopic techniques, with a focus on joint preservation and knee injuries, at the Steamboat Orthopaedic and Spine Institute (SOSI). He has gravitated toward knee injuries such as ACL tears and meniscus injuries because theyre prevalent among so many of his athletic patients.

My practice is about saving lifestyles, not lives. Were giving people the function theyre seeking to pursue the lifestyle they want. Dr. Alex Meininger

I enjoy taking care of athletic people and the problems common to them, he said. Ive developed my practice as a knee specialist to care for complex and advanced injuries, and also as an educator of arthroscopic surgery.

Saving lifestyles

Performing more than 500 knee surgeries a year about 150 of which are ACL reconstructions in addition to numerous hip and shoulder procedures, Dr. Meininger focuses on helping patients return to their passions.

One of the best things about being an orthopaedic surgeon is that its a tangible specialty. We identify a problem that we can see, feel and touch; and offer a repair or other ways to physically solve that problem, he said. My practice is about saving lifestyles, not lives. Were giving people the function theyre seeking to pursue the lifestyle they want.

Instructor and author

Dr. Meininger is a leader in the field of arthroscopy, serving as an Associate Masters Instructor of Arthroscopy and volunteering regularly with the Arthroscopy Association of North America (AANA).

As an instructor, I take away a lot of pearls myself just by interacting with fellow leaders in the field, he said. Meetings and conventions provide opportunities and time to brainstorm and develop new techniques.

Dr. Meininger is also a respected author of multiple scientific publications; including two books dedicated to the treatment of sports injuries, author of numerous scientific articles and an invited author of textbook chapters on orthopaedic surgical techniques. Steamboat Springs truly has access to world-class orthopaedic sports medicine care right here in our resort community.

Orthopaedics is a lifelong passion, and its truly one of the greatest things of my life, Dr. Meininger said.

Orthopaedic innovation

Dr. Meininger is an expert in joint preservation, taking measures to restore the joint and prolong longevity in order to avoid joint-replacement surgery. He uses advanced tools for regenerative medicine such as platelet-rich plasma or stem-cell injections, as well as MACI surgery, which repairs cartilage defects of the knee.

Given Steamboats active population, many patients suffer multiple injuries, Dr. Meininger said. He wants these patients to know that when injuries get complicated, SOSI can provide the latest and best treatments right here in town.

We can accomplish anything the big cities can offer, he said.

Read more from the original source:
A passion for taking care of Steamboat's active patients - Steamboat Pilot and Today

Coronavirus Researchers Discover How COVID-19 May Trigger Fatal Levels of Lung Inflammation – SciTechDaily

CT scan of patients lungs showing COVID-19 damage in red. Credit: Gerlig Widmann and team, Department of Radiology, Medical University of Innsbruck

Responding to the COVID-19 pandemic caused by the novel coronavirus, SARS-CoV-2, requires models that can duplicate disease development in humans, identify potential targets and enable drug testing. Specifically, access to primary human lung in vitro model systems is a priority since a variety of respiratory epithelial cells are the proposed targets of viral entry.

Now, a team of infectious disease, pulmonary and regenerative medicine researchers at Boston University, studying human stem cell-derived lung cells called type 2 pneumocytes, infected with SARS-CoV-2, have shown that the virus initially suppresses the lung cells ability to call in the help of the immune system with interferons to fight off the viral invaders and instead activates an inflammatory pathway called NFkB. The infected lung cells pour out inflammatory proteins. In the body of an infected person, those proteins drive up levels of inflammation in the lungs, explains corresponding author Darrell Kotton, MD, the David C. Seldin Professor of Medicine at BUSM and Director of the BU/BMC Center for Regenerative Medicine (CReM).

According to the researchers, the inflammatory signals initiated by the infected pneumocytes attract an army of immune cells into lung tissue laden with infected and already dead and dying cells. Our data confirms that SARS-CoV-2 blocks cells from activating one of the anti-viral branches of the immune system early on after infection has set in. The signal the cells would typically send out, a tiny protein called interferon that they exude under threat of disease, are instead delayed for several days, giving SARS-CoV-2 plenty of time to spread and kill cells, triggering a buildup of dead cell debris and other inflammation, added Kotton.

The data is based on experiments the research team performed in the laboratory of co-senior author Elke Mhlberger, PhD, associate professor of microbiology at BUSM and a researcher at BUs National Emerging Infectious Diseases Laboratories (NEIDL). Kotton and other members of the CReM have developed sophisticated models of human lung tissuethree-dimensional structures of lung cells, called lung organoids, grown from human stem cellswhich theyve used at BU and with collaborators elsewhere to study a range of chronic and acute lung diseases.

The research team, led by co-first authors, Jessie Huang, PhD, Kristy Abo, BA, Rhiannon Werder, PhD and Adam Hume, PhD, adapted an experimental model previously used to study the effects of smoking cigarettes to study the coronavirus in lung tissue. Droplets of live coronavirus were then added on top of the lung cells, infecting them from the air the way the virus infects cells lining the inside of the lungs when air containing the virus is breathed into the body. This adaptation of human stem cell-derived pneumocytes to air, known as an air-liquid interface cell culture was a key advance that allowed us to simulate how SARS-CoV-2 enters cells deep in the lungs of the most severely affected patients, said co-senior author Andrew Wilson, MD, associate professor of medicine at BUSM. Type 2 pneumocytes are also infected and injured in patients with COVID-19, making this a clinically meaningful system to understand how the disease injures patient lungs.

Wilson and Kotton, are also pulmonary and critical care physicians taking care of patients with COVID-19 pneumonia at Boston Medical Center, while also leading their laboratories to produce the human lung cells that were then transported into the NEIDL. There Hume, a senior research scientist in the Mhlbergers lab, worked in a BSL-4 suit to perform the infections of the cells that the three collaborating teams then analyzed together through weekly zoom calls.

These cells are an amazing platform to study SARS-CoV-2 infection, adds Mhlberger. They likely reflect what is going on in the lung cells of COVID-19 patients. If you look at the damage SARS-CoV-2 inflicts on these cells, you definitely dont want to get the disease.

These findings appear online in the journal Cell Stem Cell.

Reference: SARS-CoV-2 Infection of Pluripotent Stem Cell-derived Human Lung Alveolar Type 2 Cells Elicits a Rapid Epithelial-Intrinsic Inflammatory Response by Jessie Huang, Adam J. Hume, Kristine M. Abo, Rhiannon B. Werder, Carlos Villacorta-Martin, Konstantinos-Dionysios Alysandratos, Mary Lou Beermann, Chantelle Simone-Roach, Jonathan Lindstrom-Vautrin, Judith Olejnik, Ellen L. Suder, Esther Bullitt, Anne Hinds, Arjun Sharma, Markus Bosmann, Ruobing Wang, Finn Hawkins, Eric J. Burks, Mohsan Saeed, Andrew A. Wilson, Elke Mhlberger and Darrell N. Kotton, 18 September 2020, Cell Stem Cell. DOI: 10.1016/j.stem.2020.09.013

Funding for this study was provided by Evergrande MassCPR awards, the National Institutes of Health, a CJ Martin Early Career Fellowship from the Australian National Health and Medical Research Council, an I. M. Rosenzweig Junior Investigator Award from the Pulmonary Fibrosis Foundation, a Harry Shwachman Cystic Fibrosis Clinical Investigator Award, the Gilead Sciences Research Scholars Program, Gilda and Alfred Slifka and Gail and Adam Slifka funds, a Cystic Fibrosis Foundation grant, and a Fast Grants award.

Follow this link:
Coronavirus Researchers Discover How COVID-19 May Trigger Fatal Levels of Lung Inflammation - SciTechDaily

City of Hope Enters Licensing Agreement With Chimeric to Develop Its Pioneering Chlorotoxin CAR T Cell Therapy – Business Wire

DUARTE, Calif.--(BUSINESS WIRE)--City of Hope, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases, today announced that it has licensed intellectual property relating to its pioneering chlorotoxin chimeric antigen receptor (CLTX-CAR) T cell therapy to Chimeric Therapeutics Limited, an Australian biotechnology company.

The therapy is currently being used in a phase 1 clinical trial at City of Hope to treat glioblastoma (GBM), a type of brain tumor. The first patient in the trial was recently dosed; Behnam Badie, M.D., chief of City of Hopes Division of Neurosurgery and The Heritage Provider Network Professor in Gene Therapy, is leading this innovative, first-of-its-kind trial.

Chimeric has acquired the exclusive worldwide rights to develop and commercialize certain patents relating to City of Hopes CLTX-CAR T cells, as well as to further develop the therapy for other cancers.

City of Hope is excited to enter into this agreement with Chimeric as it supports our innovative research in CAR T cell therapy and our commitment to extend these therapies to more patients, particularly those with GBM and other solid tumors that are difficult to treat, said Christine Brown, Ph.D., The Heritage Provider Network Professor in Immunotherapy and deputy director of City of Hopes T Cell Therapeutics Research Laboratory. Chimeric shares our goal of providing effective CAR T cell therapies to more patients with current unmet medical needs.

Led by Brown and Michael Barish, Ph.D., chair of City of Hopes Department of Developmental and Stem Cell Biology, and Dongrui Wang, Ph.D., a recent graduate of City of Hopes Irell & Manella Graduate School of Biological Sciences, the team developed and tested the first CAR T cell therapy using CLTX, a component of scorpion venom, to direct T cells to target brain tumor cells. The research was published this past March in Science Translational Medicine.

Chimeric is excited to join City of Hope in its quest to find more effective cancer therapies. This is an exceedingly rare opportunity to acquire a promising technology in one of the most exciting areas of immuno-oncology today, said Paul Hopper, executive chairman of Chimeric. Furthermore, the CLTX-CAR T cell therapy has completed years of preclinical research and development, and recently enrolled its first patient in a phase 1 clinical trial for brain cancer.

CARs commonly incorporate a monoclonal antibody sequence in their targeting domain, enabling CAR T cells to recognize antigens and kill tumor cells. In contrast, the CLTX-CAR uses a synthetic 36-amino acid peptide sequence first isolated from death stalker scorpion venom and now engineered to serve as the CAR recognition domain.

In this recent study, City of Hope researchers used tumor cells in resection samples from a cohort of patients with GBM to compare CLTX binding with expression of antigens currently under investigation as CAR T cell targets. They found that CLTX bound to a greater proportion of patient tumors, and cells within these tumors.

CLTX binding included the GBM stem-like cells thought to seed tumor recurrence. Consistent with these observations, CLTX-CAR T cells recognized and killed broad populations of GBM cells while ignoring nontumor cells in the brain and other organs. The study team demonstrated that CLTX-directed CAR T cells are highly effective at selectively killing human GBM cells without off-tumor targeting and toxicity in cell-based assays and in animal models.

City of Hope, a recognized leader in CAR T cell therapies for GBM and other cancers, has treated more than 500 patients since its CAR T program started in the late 1990s. The institution continues to have one of the most comprehensive CAR T cell clinical research programs in the world it currently has 30 ongoing CAR T cell clinical trials, including CAR T cell trials for HER-2 positive breast cancer that has spread to the brain, and PSCA-positive bone metastatic prostate cancer. It was the first and only cancer center to treat GBM patients with CAR T cells targeting IL13R2, and the first to administer CAR T cell therapy locally in the brain, either by direct injection at the tumor site, through intraventricular infusion into the cerebrospinal fluid, or both. In late 2019, City of Hope opened a first-in-human clinical trial for patients with recurrent GBM, combining IL13R2-CAR T cells with checkpoint inhibitors nivolumab, an anti-PD1 antibody, and ipilimumab, blocking the CTLA-4 protein.

Both an academic medical center and a drug development powerhouse, City of Hope is known for creating the technology used in the development of human synthetic insulin and numerous breakthrough cancer drugs. Its unique research and development hybrid of the academic and commercial creates an infrastructure that enables City of Hope researchers to submit an average of 50 investigational new drug applications to the U.S. Food and Drug Administration each year. The institution currently holds more than 450 patent families.

"City of Hope is delighted to license this technology to Chimeric, said Sangeeta Bardhan Cook, Ph.D., City of Hope director of the Office of Technology Licensing. We are impressed with the ability of their executive team to push and bring therapies to market expeditiously. At City of Hope, our mission is to transform the future of health care. We believe Chimeric has the vision to offer innovative therapies to cancer patients.

About City of Hope

City of Hope is an independent biomedical research and treatment center for cancer, diabetes and other life-threatening diseases. Founded in 1913, City of Hope is a leader in bone marrow transplantation and immunotherapy such as CAR T cell therapy. City of Hopes translational research and personalized treatment protocols advance care throughout the world. Human synthetic insulin and numerous breakthrough cancer drugs are based on technology developed at the institution. A National Cancer Institute-designated comprehensive cancer center and a founding member of the National Comprehensive Cancer Network, City of Hope has been ranked among the nations Best Hospitals in cancer by U.S. News & World Report for 14 consecutive years. Its main campus is located near Los Angeles, with additional locations throughout Southern California. For more information about City of Hope, follow us on Facebook, Twitter, YouTube or Instagram.

Original post:
City of Hope Enters Licensing Agreement With Chimeric to Develop Its Pioneering Chlorotoxin CAR T Cell Therapy - Business Wire